The Effect of Delaying the Selection of Small Molecule Drugs for Medicare Drug Price Negotiation Juliette Cubanski and Tricia Neuman Published: Apr 16, 2025

https://www.kff.org/policy-watch/the-effect-of-delaying-the-selection-of-small-molecule-drugs-for-medicare-drug-price-negotiation/?utm_campaign=KFF-This-Week&utm_medium=email&_hsenc=p2ANqtz--51AjcVmd8Z-BPGn_02GRvaQyR7HhPPIaWew8Hbj6vyicpZuBgZ3OQ-WlqSQVGXQ_Xr63fUvL5YwomjBauGjJ4PL_gcA&_hsmi=357364514&utm_content=357364514&utm_source=hs_email The Effect of Delaying the Selection of Small Molecule Drugs for Medicare Drug Price Negotiation President Trump’s executive order directs the Secretary of Health and Human Services to work with Congress to implement a change in law to delay negotiation of so-called “small molecule” drugs under the Inflation Reduction Act’s Medicare Drug Price Negotiation Program for an additional four years. We analyze how many of the drugs previously selected for negotiation would not have been eligible if this policy had been in place at the time.v